Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Royalty Pharma plc reported an insider transaction involving an entity affiliated with its EVP, Research & Investments, Marshall Urist. On January 9, 2026, Sandy Lamm LLC, an entity associated with Urist, sold 20,000 Class A Ordinary Shares at a weighted average price of $40.7817 per share pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2025. After this sale, 60,000 Class A Ordinary Shares were held indirectly through Sandy Lamm LLC, 19,020 shares were held indirectly through an IRA, and 7,398 shares were held directly.
Royalty Pharma has a planned Rule 144 sale of 495860 shares of common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 20523645.4 and 427247489 shares outstanding. The shares are expected to be sold on or about 01/07/2026 on NASD. They were originally acquired from the issuer in a private transaction on 06/16/2020, with 495860 shares received on that date.
Over the past 3 months, the person for whose account the securities are to be sold and related entities have already sold multiple blocks of common stock, including 3000 shares on 11/19/2025 for gross proceeds of 113364 and 110000 shares on 12/03/2025 for 4375008. Additional sales by entities such as GWL 2014 G LLC, GWL 2020 G LLC, GWL 2023 G HoldCo LLC, and GWL 2021 G LLC are also listed, reflecting an ongoing disposition program.
Royalty Pharma plc’s EVP & CFO Terrance P. Coyne reported indirect sales of Class A Ordinary Shares through entities associated with him. On January 2, 2026, TPC RP 2021, LLC sold 65,832 Class A shares and TPC RP EPA1 LLC sold 3,750 Class A shares, both at a weighted average price of $38.4157 per share, under a Rule 10b5-1 trading plan adopted on August 8, 2025.
After these trades, TPC RP 2021, LLC held 460,828 Class A shares and TPC RP EPA1 LLC held 39,760 Class A shares, reported as indirect holdings for Coyne. Additional indirect holdings include shares held through the reporting person’s and spouse’s IRAs and by the spouse, as well as partnership and Royalty Pharma Holdings Ltd interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the latter subject to vesting conditions.
Royalty Pharma plc executive Marshall Urist, EVP of Research & Investments, reported selling 20,000 Class A Ordinary Shares on December 16, 2025. The sale, coded as "S," was executed at a weighted average price of $38.321 per share, with individual trades ranging from $38.24 to $38.40. All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
Following this activity, Urist reports beneficial ownership of 140,000 Class A shares indirectly through Sandy Lamm LLC, 19,020 shares indirectly through an IRA, and 7,398 shares held directly. In addition, Urist and related family vehicles hold limited partnership interests exchangeable into 2,474,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into a further 1,356,528 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc executive vice president and chief financial officer Terrance P. Coyne reported selling Class A ordinary shares of Royalty Pharma plc on 12/15/2025 under a pre-arranged Rule 10b5-1 trading plan. The filing shows a sale of 65,832 Class A shares at a weighted average price of
After these transactions, Coyne continues to report indirect beneficial ownership of 526,660 Class A shares through TPC RP 2021, LLC and 43,510 Class A shares through TPC RP EPA1 LLC, along with additional holdings in IRA and spouse accounts. The remarks also state that entities controlled by him hold interests exchangeable into 6,448,180 Class A shares and Class E shares exchangeable into 1,807,277 Class A shares, with the Class E shares subject to vesting conditions.
Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of
After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on
Royalty Pharma plc executive George W. Lloyd, EVP, Investments & CLO, reported multiple sales of Class A Ordinary Shares of RPRX on 11/19/2025. The transactions, coded as open-market sales, were executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, meaning they followed a pre-set schedule. Shares were sold indirectly through several family-related entities, with weighted average prices generally between about $37.77 and $39.34 per share, and smaller sales from directly held shares.
After the reported sales, Lloyd continues to hold Class A Ordinary Shares through multiple vehicles, as well as limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. He also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of Class A Ordinary Shares of Royalty Pharma plc (RPRX) on 11/17/2025. The transactions, made under a Rule 10b5-1 trading plan adopted on August 8, 2025, included the sale of 65,844 Class A Ordinary Shares by TPC RP 2021, LLC at a weighted average price of $39.3041 per share and 3,750 Class A Ordinary Shares by TPC RP EPA1 LLC at a weighted average price of $39.304 per share.
Following these trades, the filing reports 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC and 54,760 Class A Ordinary Shares held indirectly through TPC RP EPA1 LLC, along with additional indirect and direct holdings through IRAs, a spouse’s IRA, and personal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd that may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.
Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.
Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.
Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
